Aclaris Therapeutics to Participate in Two February Healthcare Conferences [Yahoo! Finance]
Aclaris Therapeutics to Participate in Two February Healthcare Conferences
Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by analysts at Craig Hallum to a "strong-buy" rating.
Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPa Monoclonal Antibody for Advanced Solid Tumors [Yahoo! Finance]
Aclaris Therapeutics (NASDAQ:ACRS) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.